NZ602380A - Peptides for vaccine against birch allergy - Google Patents
Peptides for vaccine against birch allergyInfo
- Publication number
- NZ602380A NZ602380A NZ602380A NZ60238011A NZ602380A NZ 602380 A NZ602380 A NZ 602380A NZ 602380 A NZ602380 A NZ 602380A NZ 60238011 A NZ60238011 A NZ 60238011A NZ 602380 A NZ602380 A NZ 602380A
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptides
- vaccine against
- against birch
- birch allergy
- variant
- Prior art date
Links
- 235000018185 Betula X alpestris Nutrition 0.000 title abstract 2
- 235000018212 Betula X uliginosa Nutrition 0.000 title abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 2
- 208000026935 allergic disease Diseases 0.000 title abstract 2
- 230000007815 allergy Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1002559.1A GB201002559D0 (en) | 2010-02-15 | 2010-02-15 | Birch peptides for vaccine |
| PCT/GB2011/000206 WO2011098778A2 (en) | 2010-02-15 | 2011-02-15 | Peptides for vaccines against birch allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602380A true NZ602380A (en) | 2014-10-31 |
Family
ID=42110757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602380A NZ602380A (en) | 2010-02-15 | 2011-02-15 | Peptides for vaccine against birch allergy |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9017689B2 (enExample) |
| EP (2) | EP3056213A1 (enExample) |
| JP (2) | JP5926198B2 (enExample) |
| KR (1) | KR20120120965A (enExample) |
| CN (1) | CN102762225B (enExample) |
| AU (1) | AU2011214104B2 (enExample) |
| CA (2) | CA3139588A1 (enExample) |
| DK (1) | DK2536429T3 (enExample) |
| EA (1) | EA201290792A1 (enExample) |
| ES (1) | ES2573651T3 (enExample) |
| GB (2) | GB201002559D0 (enExample) |
| HR (1) | HRP20160481T1 (enExample) |
| HU (1) | HUE029138T2 (enExample) |
| IL (1) | IL221196A0 (enExample) |
| MX (1) | MX2012009431A (enExample) |
| NZ (1) | NZ602380A (enExample) |
| PL (1) | PL2536429T3 (enExample) |
| SG (1) | SG183198A1 (enExample) |
| SI (1) | SI2536429T1 (enExample) |
| WO (1) | WO2011098778A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201002559D0 (en) * | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| JP2015509487A (ja) * | 2012-02-07 | 2015-03-30 | ラ ホーヤ インスティテュート フォー アレルギー アンド イムノロジーＬａ Ｊｏｌｌａ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ａｌｌｅｒｇｙ Ａｎｄ Ｉｍｍｕｎｏｌｏｇｙ | アレルゲンタンパク質由来のエピトープ並びに免疫応答モジュレーションのための方法及び使用 |
| GB201209862D0 (en) | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| GB201211586D0 (en) * | 2012-06-29 | 2012-08-15 | Circassia Ltd | Japanese cedar peptides for preventing or treating allergy |
| US20150088644A1 (en) | 2013-09-23 | 2015-03-26 | Facebook, Inc., a Delaware corporation | Predicting User Interactions With Objects Associated With Advertisements On An Online System |
| CN106699584B (zh) * | 2016-12-30 | 2018-06-26 | 南京农业大学 | 一种利用花粉作为天然催化剂制备的γ-氨基丁酸及其制备方法和应用 |
| NZ759513A (en) | 2017-06-01 | 2022-01-28 | Regeneron Pharma | Human antibodies to bet v 1 and methods of use thereof |
| CN110175468B (zh) * | 2019-05-05 | 2020-12-01 | 浙江工业大学 | 一种保留分布特征的姓名脱敏方法 |
| CN115633666B (zh) * | 2021-07-19 | 2025-11-18 | 四川大学华西医院 | 人源化双致敏动物模型和系统性过敏动物模型的构建方法及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| WO1994001560A1 (en) | 1991-07-12 | 1994-01-20 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
| US5968526A (en) | 1994-04-14 | 1999-10-19 | Immulogic Pharamaceutical Corporation | T cell epitopes of the major allergens from Dermatophagoides (house dust mite) |
| WO1999034826A1 (en) | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
| FR2788698B1 (fr) | 1999-01-27 | 2001-03-30 | Commissariat Energie Atomique | Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant |
| ES2316632T3 (es) | 2001-12-05 | 2009-04-16 | Circassia Limited | Metodos y sistemas inmunoterapeuticos. |
| PT1403280E (pt) | 2002-09-27 | 2005-11-30 | Biomay Prod & Handel | Vacinas hipoalergenicas baseadas no alergenio ph1 p 7 de polen de capim timoteo |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| ES2425486T3 (es) | 2007-05-09 | 2013-10-15 | Circassia Limited | Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| SI2083856T1 (sl) * | 2007-08-15 | 2011-02-28 | Circassia Ltd | Peptidi za desenzibilizacijo proti alergijam |
| US8821887B2 (en) | 2008-08-15 | 2014-09-02 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of IL-10 production |
| GB201002559D0 (en) * | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
-
2010
- 2010-02-15 GB GBGB1002559.1A patent/GB201002559D0/en not_active Ceased
-
2011
- 2011-02-15 CA CA3139588A patent/CA3139588A1/en active Pending
- 2011-02-15 CA CA2789353A patent/CA2789353A1/en not_active Abandoned
- 2011-02-15 SI SI201130818A patent/SI2536429T1/sl unknown
- 2011-02-15 GB GB1102657.2A patent/GB2481475B/en not_active Expired - Fee Related
- 2011-02-15 HR HRP20160481TT patent/HRP20160481T1/hr unknown
- 2011-02-15 EP EP15200538.5A patent/EP3056213A1/en not_active Withdrawn
- 2011-02-15 SG SG2012058228A patent/SG183198A1/en unknown
- 2011-02-15 KR KR1020127024247A patent/KR20120120965A/ko not_active Ceased
- 2011-02-15 EA EA201290792A patent/EA201290792A1/ru unknown
- 2011-02-15 NZ NZ602380A patent/NZ602380A/en not_active IP Right Cessation
- 2011-02-15 WO PCT/GB2011/000206 patent/WO2011098778A2/en not_active Ceased
- 2011-02-15 HU HUE11730036A patent/HUE029138T2/hu unknown
- 2011-02-15 CN CN201180009545.3A patent/CN102762225B/zh not_active Expired - Fee Related
- 2011-02-15 JP JP2012553390A patent/JP5926198B2/ja not_active Expired - Fee Related
- 2011-02-15 PL PL11730036.8T patent/PL2536429T3/pl unknown
- 2011-02-15 MX MX2012009431A patent/MX2012009431A/es active IP Right Grant
- 2011-02-15 ES ES11730036.8T patent/ES2573651T3/es active Active
- 2011-02-15 EP EP11730036.8A patent/EP2536429B1/en not_active Not-in-force
- 2011-02-15 AU AU2011214104A patent/AU2011214104B2/en not_active Ceased
- 2011-02-15 US US13/578,888 patent/US9017689B2/en active Active
- 2011-02-15 DK DK11730036.8T patent/DK2536429T3/en active
-
2012
- 2012-07-31 IL IL221196A patent/IL221196A0/en unknown
-
2015
- 2015-03-31 US US14/674,370 patent/US20150196635A1/en not_active Abandoned
-
2016
- 2016-03-04 JP JP2016042511A patent/JP2016166194A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602380A (en) | Peptides for vaccine against birch allergy | |
| DE602008002693D1 (de) | Vakzine-peptid-kombinationen gegen katzenallergie | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
| EP4417256A3 (en) | Materials and methods for improving lung function | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| IL223867B (en) | Recombinant human follicle stimulating hormone, compositions comprising the same and uses thereof | |
| MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
| NZ594268A (en) | Grass peptides for vaccine | |
| GB201118201D0 (en) | Novel peptides | |
| PH12018500368A1 (en) | Preparations containing amorphous emodepside | |
| WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
| NZ594198A (en) | Neil3 peptides and vaccines including the same | |
| EP2552462A4 (en) | CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS | |
| MX347911B (es) | Vacuna contra virus de diarrea viral de bovinos. | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| EP4226936A3 (en) | Non-neuroinvasive viruses and uses thereof | |
| WO2012048115A3 (en) | Polypeptides and their use in treating and limiting respiratory syncytial virus infection | |
| WO2012125525A3 (en) | Equine rhinitis vaccine | |
| GB0818080D0 (en) | Immunogenic peptides | |
| GB201004677D0 (en) | New salt | |
| WO2012088210A3 (en) | Methods and compositions for wound treatment | |
| WO2015054217A3 (en) | Methods and uses for reducing an allergic response in a subject | |
| AR116040A2 (es) | Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 FEB 2016 BY AJ PARK Effective date: 20150311 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 FEB 2017 BY CPA GLOBAL Effective date: 20151231 |
|
| LAPS | Patent lapsed |